Diabetes Drug

Novo Nordisk set to launch diabetes drug Ozempic in India this month

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight los

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Anti-obesity diabetes drugs receive WHO's essential medicine tag

WHO adds GLP-1 drugs for type 2 diabetes to its Essential Medicines List, as Indian pharma firms prepare to launch generics amid surging demand and patent expirations

Generic glut leads to numerous price actions on diabetes medications

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

Emcure enters distribution agreement with Sanofi for diabetes drugs

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Anti-obesity drug Mounjaro now in India: Know details here

India gets yet another diabetes and obesity management drug- a popular competitor of Ozempic that has been available in India. Watch the video to know the details.

Morepen Labs shares skyrocket 12% on rolling out 'Empamore'; details here

The uptick in the Morepen Labs share came after the company announced that it has rolled out 'Empamore.'

Key diabetes drug price crashes by up to 90% as generics enter market

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

India's health at a sugar tipping point, 50% see glucose imbalance

According to a report by diagnostic service provider Thyrocare, 49.43 per cent of the tested population in India exhibited abnormal blood glucose levels

Zerodha CEO Nithin Kamath sounds alarm on India's diabetes crisis

Kamath revealed that a 20-year-old woman living in a city today has a 64.6 per cent chance of developing diabetes in her lifetime, while for young men, the risk is 55.5 per cent

World Diabetes Day 2024: Theme, history and best winter foods for patients

Every year on November 14, we observe the World Diabetes Day (WDD) to increase awareness of diabetes, a chronic condition that affects millions of people worldwide

No suicidal thoughts link to diabetes, obesity drugs, finds UK regulator

The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data for the class of drugs, known as GLP-1 receptor agonists, more than a year ago

Certain diabetes medicines could help ward off dementia, suggests new study

Because the study was only observational, it cannot ascertain cause and effect between the drug and the impact on dementia risk. The scientists have called for clinical trials to now be carried out

Antidiabetic drug Semaglutide linked to potential vision loss: Study

Researchers say future study required to assess causality